Senate committee substitute to the 1st edition makes the following changes.

Changes the definition of CLIA-waived test under GS 90-85.3 so that it now means a laboratory test authorized by the FDA and waived under the Clinical Laboratory Improvement Amendments of 1988.

Amends GS 90-85.3A to also allow a pharmacist to order and perform a CLIA-waived test for streptococcus infections; also clarifies that a pharmacist may initiate treatment for both the flu and streptococcus infections based on the results of the CLIA-waived test. Adds to the requirement that a health benefit plan cover services provided by a pharmacist when the two specified conditions are met, that the coverage must be at no less than the same rate as any other healthcare provider performing the same service. Adds that an insurer must accept a claim under the statute regardless of whether it is submitted by a pharmacist or a pharmacy submitting the claim on behalf of a pharmacist the pharmacy employs or contracts with.

Removes the current provision requiring the State Health Director to consult with the Board of Pharmacy and Medical Board in developing statewide protocols for implementing the changes to GS 90-85.3A. Instead, requires the Medical Board and Board of Pharmacy, by October 1, 2025, to adopt rules to implement Section 1 of this act, which contains the changes to GS 90-85.3 and GS 90-85.3A, including at least the five specified measures, including an approved course of treatment pharmacists can implement for the flu and streptococcus infections, and patient parameters necessitating referral to a primary, urgent, or emergency care provider.

Changes the act’s short title.